Icon Group brings together over 30 years’ experience in research and a dedication to providing research opportunities and access to clinical trials to as many people as possible, as close to home as possible.
We provide patients and clinicians with access to national and international clinical trials across medical oncology, haematology and radiation oncology, as well as unique Icon Investigator-Initiated trials. Icon is proud to operate the largest Phase I clinical trials program and has continued to lead the way in first in-human trials helping to evolve the future of cancer treatments.
The 2020 acquisition of Ashford Cancer Centre Research by Icon Group increased Icon’s clinical trial delivery by 50%, supporting the development of new and novel therapies for people with cancer in Australia and across the world.